Targeting annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary.
BACKGROUND
Epithelial ovarian cancer (EOC) is the leading cause of death from gynecological malignancies in Western countries. Among the four major histological subtypes of EOC, clear cell carcinoma (CCC) of the ovary is highly resistant to platinum-based chemotherapy and is consequently associated with poor patient prognosis in advanced stages.


METHODS
An overview of the clinical characteristics of ovarian CCC; the role of annexin family proteins in tumor development and progression; the role of annexin A4 in enhancing cellular drug resistance; recent studies linking annexin A4 overexpression to chemoresistance in tumors of ovarian CCC.


RESULTS
Insight into the emerging role for annexin A4 in enhancing chemoresistance in ovarian CCC.


CONCLUSIONS
Annexin A4 enhances cancer cell chemoresistance and is overexpressed in tumors of patients with ovarian CCC. Targeting of annexin A4 may represent a future strategy to counteract resistance to chemotherapy in ovarian CCC.
Kim
Ayako
A
National Institute of Biomedical Innovation, Ibaraki, Osaka, Japan. ahjaringo@hotmail.com
Serada
Satoshi
S
Enomoto
Takayuki
T
Naka
Tetsuji
T
D018262:Adenocarcinoma, Clear Cell / Q000188:drug therapy* / Q000503:physiopathology; D017314:Annexin A4 / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000494:pharmacology; D018450:Disease Progression; D016503:Drug Delivery Systems; D019008:Drug Resistance, Neoplasm; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000503:physiopathology
D017314:Annexin A4; D000970:Antineoplastic Agents